 |
|
The FDA and Drug Safety
A Proposal for Sweeping Changes
Curt D. Furberg, MD, PhD;
Arthur A. Levin, MPH;
Peter A. Gross, MD;
Robyn S. Shapiro, JD;
Brian L. Strom, MD, MPH
Arch Intern Med. 2006;166:1938-1942.
The current Food and Drug Administration (FDA) system of regulating drug safety has serious limitations and is in need of changes. The major problems include the following: the design of initial preapproval studies lets uncommon, serious adverse events go undetected; massive underreporting of adverse events to the FDA postmarketing surveillance system reduces the ability to quantify risk accurately; manufacturers do not fulfill the majority of their postmarketing safety study commitments; the FDA lacks authority to pursue sponsors who violate regulations and ignore postmarketing safety study commitments; the public increasingly perceives the FDA as having become too close to the regulated pharmaceutical industry; the FDA's safety oversight structure is suboptimal; and the FDA's expertise and resources in drug safety and public health are limited. To address these problems, we urge Congress, which is ultimately responsible for the FDA's performance, to implement the following 5 recommendations: (1) give the FDA more direct legal authority to pursue violations, (2) authorize the adoption of a conditional drug approval policy, at least for selected drugs, (3) provide additional financial resources to support the safety operations, (4) mandate a reorganization of the agency with emphasis on strengthening the evaluation and proactive monitoring of drug safety, and (5) require broader representation of safety experts on the FDA's advisory committees.
Author Affiliations: Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC (Dr Furberg); Center for Medical Consumers, New York, NY (Mr Levin); Departments of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ, and New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark (Dr Gross); Center for the Study of Bioethics, Medical College of Wisconsin, Milwaukee (Dr Shapiro); and Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, and Center for Education and Research in Therapeutics, University of Pennsylvania School of Medicine, Philadelphia (Mr Strom).
RELATED LETTERS
Sweeping Changes to Food and Drug Administration and Drug Safety Regulations
James T. Cross
Arch Intern Med. 2007;167(7):732.
EXTRACT
| FULL TEXT
Avoiding the Regulatory Capture of the Food and Drug Administration
David S. Egilman, Amos H. Presler, and Claire S. Valentin
Arch Intern Med. 2007;167(7):732-733.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Observational evidence for determining drug safety
Freemantle and Irs
BMJ 2008;336:627-628.
FULL TEXT
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
Moore et al.
Arch Intern Med 2007;167:1752-1759.
ABSTRACT
| FULL TEXT
Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT
| FULL TEXT
Sweeping Changes to Food and Drug Administration and Drug Safety Regulations
Cross
Arch Intern Med 2007;167:732-732.
FULL TEXT
Avoiding the Regulatory Capture of the Food and Drug Administration
Egilman et al.
Arch Intern Med 2007;167:732-733.
FULL TEXT
Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association
Antman et al.
Circulation 2007;115:1634-1642.
FULL TEXT
REPLY
Stafford-Smith
Canadian J. Anesthesia 2007;54:77-77.
FULL TEXT
Critical Limb Ischemia and Stem Cell Research: Anchoring Hope With Informed Adverse Event Reporting
Hirsch
Circulation 2006;114:2581-2583.
FULL TEXT
|
